Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

1996

Effect of transforming growth factor-β1, fibronectin
and plasminogen activator inhibitor on migration
of bovine aortic endothelial cells
Christine E. Brozowski
Yale University

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Brozowski, Christine E., "Effect of transforming growth factor-β1, fibronectin and plasminogen activator inhibitor on migration of
bovine aortic endothelial cells" (1996). Yale Medicine Thesis Digital Library. 2428.
http://elischolar.library.yale.edu/ymtdl/2428

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

YALE MEDICAL LIBRARY

08676 1013

■EFFECT-OS
: fibrone

GROWTH FACT
ACTIVA
PLASM iNOGli

OVINE.AORTIC' ENDOTHEUAi

CHRISTINE

YALE
UNIVERSITY

CUSHING/WHITNEY
MEDICAL LIBRARY

Digitized by the Internet Archive
in 2017 with funding from
The National Endowment for the Humanities and the Arcadia Fund

https://archive.org/details/effectoftransforOObroz

Effect

of Transforming Growth Factor-pl,

Fibronectin

and Plasminogen Activator Inhibitor on Migration of
Bovine Aortic Endothelial Cells.

A Thesis Submitted to the
Yale University School of Medicine
in Partial Fulfillment of the Requirements for the
Degree of Doctor in Medicine

by
Christine E.

Brozowski

May 1996

VALE MEDICAL LIBRARY
AUG 1 3 1996

HEP
"T113
+ YIZ
bis 7

Abstract

EFFECT

OF

TRANSFORMING

PLASMINOGEN ACTIVATOR
ENDOTHELIAL
A.

CELLS.

Madri).

of Medicine,

Restenosis
and

procedures
lead

to

of

New Haven,

CT.

the

Pathology,

largest

and

formation

proliferation,
of

have

influence
The

of

this

transforming

growth

factor

University,

School

of

endarterectomy

trauma

of

a

have

cells

investigation
(TGF-(3l),

and

was

the

Later
of

studies

50ug/ml

which was

in

using a

significantly
our

resulted

a

student's

decrease

laboratory
in

to

effect
(Fn) ,

of
and

TGF- (31 decreased migration by 28%

significant
not

shown

on migration of bovine

were

did

the

endothelial

fibronectin

(PAI-2)

cell

and

been

Fibronectin decreased migration by 19% +. 4%.

lOug/ml

by

neointima.
muscle

3%.

(p<0.05)

caused

synthesis,

factors

muscle

plasminogen activator inhibitor
aortic endothelial cells.

Joseph

smooth

matrix

Growth

smooth

target

on

and

on

by

Vascular

development

depends

endothelium.

BOVINE AORTIC

(Sponsored

Yale

AND

in deundation injury which may

the

migration,

presence

FIBRONECTIN

complication

angioplasty.

hyperplasia

an

Brozowski

such as these result

Neointimal

cells.

Christine

catheter

FACTOR-(3l,

INHIBITOR ON MIGRATION OF

Department

remains

balloon

GROWTH

using

decreased

statistically significant.

Both values

t-test.

migration
higher

migration

(6%

levels
of

+

10%

PAI-2

at

± 4%).
of
+

PAI-2
3%,

TGF-(3l has been shown to

be

present

in

injury in vivo.
migration

and

migration.
vascular

significant

increases

the

rate

is

mediated

this
by

sites

of

increases

the

likelihood

smooth

suggests

that

modulation

of

the

of

effects

of

vascular

endothelial

the presence of TGF-(3l at

fibronectin can partially mimic
migration,

at

TGF- (31 decreases the rate of

Therefore,

lesion

quantities

muscle
the

TGF-pl

the

TGF- Pi

effect

the

extracellular

on

cell

site of a

restenosis.
of

cell

on

Since
BAEC

migration

matrix.

The

effect of TGF- Pi on endothelial cell migration may also be due
to increased expression of
PAI-2

PAI or decreased uPA expression,

decreases BAEC migration.

as

2

Introduction

Balloon angioplasty, endarterectomy, and synthetic grafting are therapeutic interventions
currently performed to alleviate the effects of atherosclerosis. It has been estimated that over
350,000 coronary angioplasty procedures were performed in the United States in 1995.1
Restenosis remains the most important limitation of angioplasty, with studies suggesting that
up to 50% of patients will develop restenoses within one year, with up to 20% of patients
necessitating a repeat operation within 6 months.2,3 Procedures such as angioplasty result in
endothelial denudation injury to the blood vessel walL Stenosing intimal lesions may develop
from intimal hyperplasia which narrows the vessel lumen, and can compromise blood flow.
This ultimately results in a failure of the reconstruction.4 The formation of a neointima after
vascular injury depends on smooth muscle cell proliferation and migration and the synthesis of
a new extracellular matrix.4

The normal tunica intima is composed of endothelial cells and smooth muscle cells.5
Endothelial cells line the vascular system, forming a nonthrombogenic surface for blood flow
and covering smooth muscle cells. Smooth muscle cells compose the media of large vessels,
maintain vessel wall integrity, control vascular tone and influence endothelial cell behavior.
Following denudation injury, medial smooth muscle cells proliferate and migrate rapidly into
the intima where they synthesize components which may narrow the vessel lumen. Endothelial
cells migrate more slowly from the edges of the wound to reconstitute the damaged endothelial
cell layer and reestablish vessel wall integrity, critical to maintaining lumen patency.6 Stimuli
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which retard migration of endothelial cells and enhance the migration of smooth muscle cells
lead to the development of stenotic lesions at the site of vascular injury.7

Transforming growth factor (TGF-(3l), a component of platelet a granules, is synthesized and
secreted by endothelial and smooth muscle cells.7

TGF-[3l regulates critical cell functions

including growth, differentiation, activation, and migration.8 Specifically, TGF-(3l has been
shown to be present in significant quantities at sites of vascular injury in vivo, and markedly
inhibits endothelial cell migration and vessel wall repair following injury.9 It has been suggested
that the TGF-(3l mediated decrease in endothelial cell migration is associated with increased
expression of fibronectin (Fn) and plasminogen activator inhibitor (PAI-2)8. This report
documents the effect of transforming growth factor (TGF-(31), fibronectin (Fn),

and

plasminogen activator inhibitor (PAI-2) on migration of bovine aortic endothelial cells as an in
vitro model of re-endothelialization and repair of denudation injury such as that produced by
balloon catheter angioplasty.

Methods

Bovine aortic endothelial cells (BAEC) were isolated and cultured with DMEM and 10% fetal
calf serum (FCS). The cells were seeded into the middle of a steel fence with a known area
and allowed to attach to the underlying type I collagen matrix below, and grow to confluency
for 4-5 hours. The fence was then removed. With the loss of contact inhibition, cell migration
radially outward was initiated. The cells were covered in media alone or with media plus
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exogenous transforming growth factor (TGF-[3l) at a final concentration of 0.5 ng/mL,
plasminogen activator inhibitor (PAI-2) at a final concentration of 10 ug/ml, fibronectin (Fn) at
a final concentration of 50 ug/ml, Aprotinin at 50 ug/ml, or EACA at 50 ug/ml.

The cells

migrated radially outward for six days, and were fed with additional media plus the appropriate
growth factors at day three. Migrations were stopped 6 days post initiation of treatment. The
cultures were then washed in PBS and fixed with 10% Buffered Formalin. Cells were stained
with Harris' hematoxylin to evaluate cell migration.

Petri dishes with stained cells were placed on an overhead projector to assess surface area
covered by the cells. The surface areas were transferred to paper and a computer graphics
tablet was used to quantify surface areas obtained by overhead projection. These surface areas
were compared with known values of the initial fence area to obtain the net increase in surface
area. Maximal response was obtained using DMEM media and 10% FCS only, thus, this was
defined as the control with 100% relative migration. Migration in the presence of growth
factors (TGF-(3l, Fn, PAI-2, EACA and Aprotinin) was compared and normalized to this
value. Bar graphs were generated from mean values. The differences in means were analyzed
using a student's t-test. Statistical significance was assumed for P<0.05.

Results

Treatment with TGF-pl decreased the distance of migration of BAEC on a type 1 collagen
matrix by 28% + 3% compared to control. Fibronectin showed a 19% + 4% inhibition of
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migration distance. These were significant (p<0.05) using a student's t-test.

In contrast,

treatments with EACA, Aprotinin and EACA & Aprotinin did not show a significant decrease
in migration compared to the control group. EACA and Aprotinin are non-specific protease
inhibitors.

These results suggest that non-specific protease inhibitors do not decrease the

migration of endothelial cells. See Figure 1.

PAI-2 at lOug/ml showed only a 6% ± 4% decrease in migration which was not statistically
significant. In later BAEC migration studies in our laboratory, however, PAI-2 concentration
was increased to 50ug/ml with a significant decrease in migration of 10% + 3%. In additional
studies, Petzelbauer et al demonstrated that stable over-expression of PAI-1 protein in BAEC
using retroviral transduction resulted in a significant inhibition of BAEC migration.

The

g

resultant BAEC migration was found to decrease 23% ± 2%.

Discussion

Repair of arterial injury produced by balloon angioplasty or atherectomy leads to the
development of an intimal thickening and a subsequent narrowing of the vessel lumen.10
Neointimal formation depends on smooth muscle cell proliferation, migration, and matrix
synthesis, and the presence/absence of an endothelium4 The two major cell types of the vessel
wall, the smooth muscle cell and the endothelial cell, respond differently to injury.

Medial

SMCs begin to migrate from the media into the intima. Many cells proliferate, but up to one
half do not divide 4 Once in the intima, SMCs continue to proliferate and form a thick layer.

% Inhibition of Migration

40 -i

30 -

20

-

n=6

10

n=8

-

T

0

IF

-10
o
1
c
o
O

1—
CC
LL
o

c
LL

CVJ
<
CL

<
o
<
LU

c
'c
o
Q_
<

_c
'c
Q.

<
+
<
O
<
LU

Treatment

Figure 1

6

The resulting neointima is further enlarged by extracellular matrix components synthesized by
the smooth muscle cells.

Endothelial cells, on the other hand, migrate more slowly from

around the area of denudation to reconstitute the damaged endothelial cell layer. The cells at
the edge of the wound divide and migrate inward, but the central portion of large injuries may
remain uncovered.4'11 Importantly, proliferation of intimal smooth muscle cells ceases earlier in
areas covered by regenerating endothelium than in regions lacking an endothelium.4

Primary lesions differ from restenotic lesions in that primary lesions consist of well-organized
collagen and

ground substance, and are hypocellular, while restenotic lesions have foci of

hypercellularity consisting of proliferative vascular smooth muscle cells with associated matrix
proteins.12

These smooth muscle cells have an unusual elongated shape with processes

extending from the cells and are accompanied by significant matrix deposition composing 5060% of lesion size between the cells.12

Advanced atherosclerotic lesions show progressive

development of small denuded regions.

This loss of continuity of the endothelium in the

evolution of atherosclerosis suggests that some property of the atheromatous wall or blood
interacting with the wall is responsible for the inhibition of endothelial regeneration.1'

Both platelet deposition and growth factor release have been suggested as important events
initiating the cellular growth response after injury.12,14 A variety of growth factors have been
described in vascular smooth muscle cells and/or atherosclerotic tissue, and have, therefore,
been inferred to play a role in the development of restenosis lesions.

These include the

transforming growth factor-(3s, platelet-derived growth factors and receptors, fibroblast growth
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factors, and insulin-like growth factors.15 Platelet-derived growth factor (PDGF) has been
found to exert little effect on smooth muscle cell replication, but markedly influences the ability
of SMCs to migrate into the intima.16 TGF-(3l is a major component of platelet releasates and
is synthesized and secreted by endothelial cells and smooth muscle cells.7 TGF-(3l has been
shown to inhibit proliferation of endothelial cells, and to retard epithelial wound healing in
vitro.17 TGF-(3l influences matrix production and protease inhibitors, both of which affect
migration of endothelial cells. Additionally, TGF-(3l has been demonstrated to stimulate the
proliferation of smooth muscle cells and the production of elastin and proteoglycan, common
features of atherosclerotic plaques.15

TGF-(3l has been shown to be present in significant quantities at sites of vascular injury in
vivo.8,10,18 In addition to decreasing endothelial cell migration, TGF-(3l has been documented to
increase vascular smooth muscle cell migration.19 Stimuli which enhance migration of medial
smooth muscle cells into the intima where they can synthesize matrix components leading to
the development of a stenotic lesion at the site of vascular injury may result in the eventual
occlusion of the vessel lumen.6

Because TGF-(3l decreases the rate of endothelial cell

migration and increases the rate of smooth muscle cell migration, the presence of TGF-(3l at
the site of a vascular lesion increases the likelihood of restenosis. Additional steps involved in
restenosis include the release of growth factors, proteoglycan deposition and release of growth
factors, proteoglycan deposition and extracellular matrix remodeling.2,20 Potential inhibitors at
each step could be used as preventative therapy.

TGF-(3l influences matrix production and protease inhibitors, both of which affect migration of
endothelial cells. TGF-(3l has been observed to down-regulate the expression of uPA activity
in endothelial cellS.21

Endothelial cells express tissue-type plasminogen activator (tPA),

urokinase-like plasminogen activator (uPA) and plasminogen activator inhibitor (PA1).

uPA

interaction with the uPA receptor has been associated with an increase in endothelial cell
motility.8 PAI-2 is a protease inhibitor which is specific for uPA receptor sites, and decreases
BAEC migration. TGF-(3l decreases the expression of uPA and subsequently lessens the rate
of migration of endothelial cells. Thus, the TGF-(5l effect on BAEC migration may be due to
the combined effects of increased expression of PA1, decreased uPA expression, and
influencing the extracellular matrix (increased fibronectin deposition). In other studies in our
laboratory, Petzelbauer et al showed that unlike endothelial cells, bovine aortic smooth muscle
cells exhibited an increased rate of migration in response to the addition of exogenous TGF-(3l,
fibronectin or PAI-2, or by the stable over-expression of PAI-1 protein.

Endothelial cell replication and migration are triggered by damage to the vessel walL These
cells migrate from the leading edge of a lesion to reestablish the endothelial monolayer, and
repair the vessel wall It has been shown that TGF-(3 inhibits both endothelial replication and
migration, thus decreasing endothelial regeneration.13

Heimark,13 et al demonstrated that

TGF-(3 transiently decreases DNA synthesis in endothelial cells. Specifically, TGF-(3 delays the
entry of regenerating endothelial cells into the S phase. Once cells have passed into S or G2,
however, they are no longer responsive to TGF-(3.

9

Increased TGF-|3l gene expression has been found in rat carotid arteries after balloon catheter
injury.8,10 In studies by Nikol,15 et aL, human atherosclerotic tissue specimens were examined
for TGF-(3l mRNA.

Primary atherosclerotic lesions showed slightly, but not significantly,

higher TGF-(3l expression than non-atherosclerotic tissue. TGF-(3l was maximally expressed
in restenotic tissues. TGF-(3l expression in restenotic atherosclerotic tissues was significantly
greater than that found in primary atherosclerotic tissue, consistent with the hypothesis that
increased TGF-(3l mRNA expression is related to smooth muscle cell proliferation.15 These
results suggest a role for TGF-(3l in the development of restenosis lesions.

Neointimal formation requires the synthesis of a new extracellular matrix. Major constituents
of matrices produced by intimal SMCs include fibronectin, elastin and type I collagen.10 The
addition of exogenous TGF-(3l to arterial SMC in vitro has been shown to stimulate
extracellular protein synthesis.10 TGF-(3l has been shown to increase fibronectin production in
endothelial cells, smooth muscle cells and fibroblasts.8,22

Fibronectin promotes rapid

attachment of bovine aortic endothelial cells, but little migration.21 BAECs treated with TGF(31 have shown increased fibronectin mRNA levels, and synthesis and deposition of
fibronectin8,19. Increased mRNA levels of fibronectin and collagen a2(I) have been found to
correlate with the onset of neointimal formation.10

In this paper we have shown that the addition of exogenous TGF-(3l or fibronectin decreases
BAEC migration. Fibronectin can partially mimic the effects of TGF-(3l on BAEC migration
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suggesting that the TGF-(3l effect on migration is mediated by modulation of the synthetic
matrix. TGF-(3l alters matrix production by increasing fibronectin deposition, increasing PAI
expression, and decreasing uPA expression.8 The majority of medical therapies designed to
prevent restenosis are aimed at reducing smooth muscle cell migration as the primary cause of
restenoses pathology. However, enhancement of endothelial cell regeneration and decreased
matrix production are other potential targets to consider as proliferation of smooth muscle cells
ceases earlier in areas covered by an regenerating endothelium, and as the matrix composes a
large part of the lesion volume.

Conclusion

This paper has demonstrated that TGF-(3l and fibronectin inhibit migration of bovine aortic
endothelial cells. Other studies in our laboratory have shown that the addition of exogenous
PAI-2 in high concentration (50ug/ml) also decreased BAEC migration, and that PAI & TGF(31, and Fn & TGF-(3l were not additive. Therefore, we surmise that TGF-(3l alters matrix
production by increasing fibronectin deposition, increasing PAI-2 expression and decreasing
uPA expression. Conversely, TGF-(3l has been shown to enhance migration in smooth muscle
cells.

Previous studies have shown that the most intimal smooth muscle cell proliferation

occurs in the region last covered by regenerating endothelium.24,25 Therefore, stimuli which
retard the migration of endothelial cells and enhance the migration of smooth muscle cells lead
to the development of stenotic lesions at the site of vascular injury. Consequently, reducing the
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TGF-pl burden at the site of vascular lesion may decrease the incidence of restenosis following
vascular injury.
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